News & Updates

Show Multimedia Only

Apixaban, aspirin equally good at preventing ischaemic, bleeding events in patients with cancer history

18 Aug 2024

The risk of major ischaemic and haemorrhagic events in patients with a history of cancer and cryptogenic stroke appears to be similar between those on apixaban and those on aspirin, according to a post hoc analysis of the ARCADIA* trial.

18 Aug 2024

Navitoclax–ruxolitinib combo doubles spleen response rates in myelofibrosis

17 Aug 2024 by

In untreated myelofibrosis, using navitoclax in combination with ruxolitinib appears to result in a twofold increase in the number of patients experiencing spleen volume shrinkage, regardless of prognosis, according to updated data from the phase III TRANSFORM-1 trial.

17 Aug 2024

AI improves physician accuracy in identifying prostate cancer extent

16 Aug 2024 by

Use of artificial intelligence (AI)-assisted cancer contours helps minimize underestimation of the extent of prostate cancer, thereby improving the physician’s ability in terms of contouring accuracy and negative margin rate, a study has shown.

16 Aug 2024

High olive oil intake helps promote longer life

16 Aug 2024

Regular consumption of olive oil may provide protective benefits against cancer, cardiovascular, and all-cause mortality, independent of overall diet quality, suggests a study.

16 Aug 2024

SG study underscores use of germline testing to guide cancer therapeutics

16 Aug 2024 by

A study conducted at the Cancer Genetics Clinic of the National University Cancer Institute, Singapore underlines the use of germline genetic testing in guiding therapeutic decisions in individuals with advanced cancers.

16 Aug 2024

mPFS approaches 4 years with 1L durvalumab- and olaparib-incorporating 5-drug combo in aEOC

16 Aug 2024 by

In patients with HRD+ advanced epithelial OC harbouring BRCA wild-type tumours, integrating durvalumab induction and durvalumab plus olaparib maintenance into 1L bevacizumab-containing chemotherapy significantly extends PFS and PFS2, suggest updated results from the DUO-O trial.

16 Aug 2024

Add-on olanzapine augments nausea, vomiting control during chemo cycles

14 Aug 2024 by

Adding olanzapine to prophylactic antiemetic medications appeared to substantially improve nausea and vomiting control among patients receiving moderately emetogenic chemotherapy (MEC) regimens in a phase III randomized clinical trial.

14 Aug 2024

Chemo plus liver transplant prolongs survival in unresectable colorectal liver metastases

13 Aug 2024 by

Liver transplantation (LT) in combination with chemotherapy, as opposed to chemotherapy alone, can provide a meaningful improvement in survival among patients with unresectable colorectal liver metastases, suggest the results of the TRANSMET trial presented at ESMO GI 2024.

13 Aug 2024